GLP-1 medications and SARMs (selective androgen receptor modulators) both circulate heavily in online fitness and biohacking content, sometimes in the same videos or product catalogs, which creates a persistent impression that they're similar categories of compound. They aren't, and conflating them obscures real differences in chemistry, evidence, and legal status.

They're Not Even the Same Type of Molecule

GLP-1 drugs like semaglutide and tirzepatide are peptides, chains of amino acids that mimic the body's own incretin hormones and act on GLP-1 and related receptors to affect appetite and blood sugar. SARMs are small synthetic organic molecules, chemically unrelated to peptides, designed to bind the androgen receptor, the same receptor testosterone and anabolic steroids act on, with the goal of selectively stimulating muscle and bone tissue while limiting effects on other androgen-sensitive tissue. The only real similarity is that both are sometimes grouped under a loose "peptides and performance compounds" umbrella in marketing, despite having nothing in common mechanistically.

Regulatory Status: An Entirely Different Picture

Multiple GLP-1 drugs are FDA-approved prescription medications for type 2 diabetes, obesity, or both, with specific approved formulations, indications, and prescribing information. No SARM has FDA approval for any human use. The FDA has issued public warnings about SARMs specifically, and several SARM compounds have been the subject of FDA warning letters and seizures for being marketed as dietary supplements, which they cannot legally be classified as under federal law as unapproved drug ingredients. SARMs are also explicitly prohibited by the World Anti-Doping Agency, placing them in a very different category from GLP-1 drugs, which are not prohibited in competitive sports and are, in fact, prescribed to athletes for legitimate medical reasons like diabetes.

The Evidence Base Is Also Different

GLP-1 drugs have been through the large, randomized, placebo-controlled Phase 3 trial programs required for FDA approval, covering tens of thousands of patients across years of data on efficacy and side effects. SARMs, by contrast, have a comparatively thin human clinical trial record; most of what's publicly known about their effects in humans comes from a small number of early-phase trials for specific medical indications like muscle wasting, conducted by pharmaceutical sponsors that in most cases did not pursue the compounds to approval, alongside a much larger body of anecdotal use outside any clinical trial setting.

Why the Confusion Persists

Both categories get sold through similar channels, online research-chemical vendors, compounding-adjacent telehealth operations, and fitness-influencer affiliate links, and both attract buyers interested in body composition or performance. That overlap in distribution and audience is almost certainly why they end up discussed together, even though an FDA-approved diabetes and obesity drug and an unapproved experimental androgen-receptor compound have essentially nothing else in common.

The Bottom Line

If you see GLP-1 drugs and SARMs discussed interchangeably, that's a signal the source is organizing content by marketing category rather than by chemistry, evidence, or legal status, three things that actually separate these compounds sharply. Anyone considering either category of compound for a non-approved use should talk to a doctor about the specific evidence and risk for their own situation rather than treating "it's a peptide" or "it's a SARM" as a single, interchangeable judgment.